Tarsus Pharmaceuticals, Inc.
TARS
Rang in aandelen
#4646
Tarsus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical firm... Tarsus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical firm dedicated to advancing and commercializing innovative therapies, primarily focusing on ocular conditions. Its leading investigational drug, TP-03, a novel treatment currently in Phase III trials, is being developed to address blepharitis specifically caused by Demodex mite infestations, as well as meibomian gland disease. Beyond this, Tarsus is also progressing TP-04 for rosacea and TP-05, which targets Lyme disease prevention and aims to reduce community-level malaria. A core element of its development strategy involves lotilaner, a compound utilized to tackle a variety of human diseases across diverse therapeutic areas, encompassing eye care, dermatology, and other medical fields. Established in 2016, the company maintains its headquarters in Irvine, California.
Aandeelprijs
$69.68
Marktkapitalisatie
$3.26B
Verandering (1 dag)
2.36%
Verandering (1 jaar)
-4.46%
Land
US
Handel Tarsus Pharmaceuticals, Inc. (TARS)
Categorie
Healthcare
EPS voor Tarsus Pharmaceuticals, Inc. (TARS)
EPS per June 2026 TTM: $-1.09
Volgens de laatste financiële rapporten en de aandelenkoers van Tarsus Pharmaceuticals, Inc. is de huidige EPS van het bedrijf (TTM) $-1.09. Eind 2023 had het bedrijf een EPS van $-4.62, een stijging ten opzichte van de EPS van 2022 die $-2.52 bedroeg.
EPS-geschiedenis van Tarsus Pharmaceuticals, Inc. van 2018 tot 2026
EPS aan het einde van elk jaar
| Jaar | EPS | Wijzigen |
|---|---|---|
| 2026 (TTM) | $-1.09 | -64.50% |
| 2024 | $-3.07 | -33.55% |
| 2023 | $-4.62 | 83.33% |
| 2022 | $-2.52 | 276.12% |
| 2021 | $-0.67 | -49.24% |
| 2020 | $-1.32 | 450.00% |
| 2019 | $-0.24 | -22.58% |
| 2018 | $-0.31 | 0.00% |
EPS van vergelijkbare bedrijven of concurrenten
| Bedrijf | EPS | EPS-verschil | Land |
|---|---|---|---|
| $17.32 | -1,688.99% |
US
|
|
| $-7.98 | 632.11% |
US
|
|
| $-5.29 | 385.32% |
AU
|
|
| - | - |
CH
|
|
| $27.74 | -2,644.95% |
NL
|
